In the setting of interleukin-2 (IL-2) administration, tachycardias of ventricular origin are classified as serious, grade IV toxicities, necessitating the discontinuation of therapy. In this report, we describe a patient with renal cell carcinoma who experienced ventricular tachycardia while undergoing treatment with high-dose bolus IL-2. Prophylaxis with sotalol permitted the successful completion of his first cycle of treatment, without any recurrent rhythm disturbances.
From the Department of Medicine, Roswell Park Cancer Institute (L.O., P.E., G.C.L.), Buffalo, New York; and the Department of Cardiology, Buffalo General Hospital, New York State University School of Medicine at Buffalo (E.S.), Buffalo, New York, U.S.A.
Address correspondence and reprint requests to Dr. Leslie Oleksowicz, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, U.S.A.
